Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488708 · ClinicalTrials.gov registry record · Phase 3
On Open-Label Study in Participants With Systemic Lupus Erythematosus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,518
- Enrollment target
NCT01488708: Clinical Trial Phase 3 study, sponsored by Eli Lilly and Company.
NCT01488708 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1,518 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01488708, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,518 participants
- Enrollment target
Study Summary
The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399 in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).
Primary Outcome
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
Interventions
- DRUG Placebo
- DRUG LY2127399
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,518 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Why NCT01488708 stopped before completion
NCT01488708 is an interventional study that assigns participants to a tested intervention. Its 1,518 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01488708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01488708 about?
NCT01488708 is a clinical study titled "On Open-Label Study in Participants With Systemic Lupus Erythematosus". The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399 in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).
What is the current status of trial NCT01488708?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,518 participants. The study started on 2012-01. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01488708?
The interventions under investigation include: Placebo (DRUG), LY2127399 (DRUG).
Who is sponsoring clinical trial NCT01488708?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01488708's enrollment target sits among peer trials
1,518 156th of 2000 higher than 1,845 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia